Koninklijke Philips (NYSE:PHG) Shares Sold by Paradigm Asset Management Co. LLC

Paradigm Asset Management Co. LLC decreased its position in Koninklijke Philips (NYSE:PHG) by 94.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,343 shares of the technology company’s stock after selling 36,875 shares during the period. Paradigm Asset Management Co. LLC’s holdings in Koninklijke Philips were worth $59,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. FMR LLC grew its holdings in Koninklijke Philips by 0.6% in the third quarter. FMR LLC now owns 6,138,708 shares of the technology company’s stock valued at $200,859,000 after purchasing an additional 35,935 shares during the last quarter. Bank of Montreal Can grew its holdings in Koninklijke Philips by 2,883.5% in the third quarter. Bank of Montreal Can now owns 982,199 shares of the technology company’s stock valued at $32,157,000 after purchasing an additional 949,278 shares during the last quarter. IHT Wealth Management LLC purchased a new stake in shares of Koninklijke Philips in the third quarter valued at $19,593,000. Bar Harbor Wealth Management lifted its position in shares of Koninklijke Philips by 2.1% in the fourth quarter. Bar Harbor Wealth Management now owns 308,157 shares of the technology company’s stock valued at $7,803,000 after acquiring an additional 6,281 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Koninklijke Philips by 315.0% in the third quarter. JPMorgan Chase & Co. now owns 245,729 shares of the technology company’s stock valued at $8,040,000 after acquiring an additional 186,520 shares in the last quarter. Institutional investors and hedge funds own 13.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PHG. Jefferies Financial Group upgraded Koninklijke Philips from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 29th. UBS Group upgraded Koninklijke Philips from a “neutral” rating to a “buy” rating in a report on Thursday. Finally, StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Koninklijke Philips Price Performance

Shares of NYSE PHG opened at $25.53 on Friday. Koninklijke Philips has a twelve month low of $19.75 and a twelve month high of $32.91. The company has a current ratio of 1.23, a quick ratio of 0.74 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $24.00 billion, a price-to-earnings ratio of -30.40, a price-to-earnings-growth ratio of 0.82 and a beta of 0.77. The business has a 50 day simple moving average of $26.25 and a 200-day simple moving average of $28.14.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings results on Wednesday, February 19th. The technology company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. The firm had revenue of $5.38 billion during the quarter, compared to the consensus estimate of $5.10 billion. As a group, equities research analysts expect that Koninklijke Philips will post 1.63 earnings per share for the current year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.